Skip to main content
SpringerLink
Log in

Adherence in the Treatment of HIV and Other Infectious Diseases

  • Chapter
  • First Online:
Improving Patient Treatment Adherence

  • 1609 Accesses

Abstract

Over the last decade, survival in patients with human immunodeficiency virus (HIV) has lengthened dramatically due to improvements in the robust options for antiretroviral therapy (ART) [1]. Clinicians caring for HIV-positive patients now face many of the same challenges encountered by those with other chronic conditions (e.g., cardiovascular disease, complications from diabetes, aging) [2]. One particular issue that plagues all clinicians caring for patients with chronic diseases is how to promote optimal adherence to prescribed treatment over time. Adherence to treatment for HIV has some unique features that make its assessment and measurement challenging. In this chapter, we will review the ways in which this disease differs from and is similar to other chronic diseases. Lastly, we will identify methods and techniques that clinicians may use to enhance adherence among individuals with HIV. Of note, we will be specifically focusing on issues pertaining to the treatment of HIV in the USA.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. CDC. HIV and AIDS in the United States: A picture of today’s epidemic. 2008. Available at: http://www.cdc.gov/hiv/topics/surveillance/resources/reports/2007report/default.htm. Accessed January 9, 2009.

  2. Gifford AL, Groessl EJ. Chronic disease self-management and adherence to HIV medications. J Acquir Immune Defic Syndr. 2002;31:S163–S166.

    Article  PubMed  Google Scholar 

  3. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2008;1–139. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf

  4. Gross R, Bilker W, Friedman H, et al. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 2001;15:2109–2117.

    Article  PubMed  CAS  Google Scholar 

  5. Ickovics J, Cameron A, Zackin R, et al. Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antiviral Ther. 2002;7:185–193.

    Google Scholar 

  6. Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34:1115–1121.

    Article  PubMed  Google Scholar 

  7. Press N, Tyndall M, Wood E, et al. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2002;31:S112–S117.

    Article  PubMed  Google Scholar 

  8. Perno CR, Ceccherini-Silberstein F, De Luca A, et al. Virologic correlates of adherence to antiretroviral medications and therapeutic failure. J Acquir Immune Defic Syndr. 2002;31:S118–S122.

    Article  PubMed  Google Scholar 

  9. Vrijens B, Urquhart J. Patient adherence to prescribed antimicrovial drug dosing regimens. J Antimicrob Chemother. 2005;55:616–627.

    Article  PubMed  CAS  Google Scholar 

  10. Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197:S272–S278.

    Article  PubMed  Google Scholar 

  11. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998;339:307–311.

    Article  PubMed  CAS  Google Scholar 

  12. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385–394.

    Article  PubMed  CAS  Google Scholar 

  13. Shet A, Berry L, Mohri H, et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr. 2006;41:439–446.

    Article  PubMed  Google Scholar 

  14. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16:1051–1058.

    Article  PubMed  Google Scholar 

  15. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–2296.

    Article  PubMed  CAS  Google Scholar 

  16. DART Trial Team. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl. AIDS. 2008;22:237–247.

    Article  Google Scholar 

  17. Parienti JJ, Massari V, Descamps D, et al. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis. 2004;38:1311–1316.

    Article  PubMed  CAS  Google Scholar 

  18. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS. 1999;13:1099–1107.

    Article  PubMed  CAS  Google Scholar 

  19. Nieuwkerk PT, Sprangers MAG, Burger DM, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med. 2001;161:1962–1968.

    Article  PubMed  CAS  Google Scholar 

  20. Tam LWY, Chui CKS, Brumme CJ, et al. The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes. J Acquir Immune Defic Syndr. 2008;49:266–271.

    Article  PubMed  CAS  Google Scholar 

  21. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939–941.

    Article  PubMed  CAS  Google Scholar 

  22. Golin C, Liu H, Hays R, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;17:756–765.

    Article  PubMed  Google Scholar 

  23. Bangsberg DR, Charlebois ED, Grant RM, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003;17:1925–1932.

    Article  PubMed  Google Scholar 

  24. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.

    PubMed  CAS  Google Scholar 

  25. Kalichman SC, Amaral CM, Stearns H, et al. Adherence to antiretroviral therapy assessed by unannounced pill counts conducted by telephone. J Gen Intern Med. 2007;22:1003–1006.

    Article  PubMed  Google Scholar 

  26. Miller LG, Liu H, Hays RD, et al. How well do clinicians estimate patients’ adherence to combination antiretroviral therapy? J Gen Intern Med. 2002;17:1–11.

    Article  PubMed  Google Scholar 

  27. Gross R, Yip B, Lo Re V, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006;194:1108–1114.

    Article  PubMed  Google Scholar 

  28. Catz SL, Kelly JA, Bogart LM, et al. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19:124–133.

    Article  PubMed  CAS  Google Scholar 

  29. Ickovics J, Meade C. Adherence to antiretroviral therapy among patients with HIV: a critical link between behavioral and biomedical sciences. J Acquir Immune Defic Syndr. 2002;31:S98–S102.

    Article  PubMed  Google Scholar 

  30. Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002;31:S123–S127.

    Article  PubMed  Google Scholar 

  31. Sidat M, Fairley C, Grierson J. Experiences and perceptions of patients with 100% adherence to highly active antiretroviral therapy: a qualitative study. AIDS Patient Care and STDs. 2007;21:509–520.

    Article  PubMed  Google Scholar 

  32. Arnsten JH, Li X, Mizuno Y, et al. Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users. J Acquir Immune Defic Syndr. 2007;46:S64–S71.

    Article  PubMed  Google Scholar 

  33. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377–381.

    PubMed  Google Scholar 

  34. Ingersoll K. The impact of psychiatric symptoms, drug use, and medication regimen on non-adherence to HIV treatment. AIDS Care. 2004;16:199–211.

    Article  PubMed  CAS  Google Scholar 

  35. Goujard C, Bernard N, Sohier N, et al. Impact of a patient education program on adherence to HIV medication: a randomized clinical trial. J Acquir Immune Defic Syndr. 2003;34:191–194.

    Article  PubMed  Google Scholar 

  36. Falagas ME, Zarkadoulia EA, Pliatsika PA, Panos G. Socioeconomic status (SES) as a determinant of adherence to treatment in HIV infected patients: a systematic review of the literature. Retrovirology. 2008;5:13.

    Article  PubMed  Google Scholar 

  37. Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R. Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns. 2002;46:93–108.

    Article  PubMed  Google Scholar 

  38. Trotta MP, Ammassari A, Melzi S, et al. Treatment-related factors and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2002;31:S128–S131.

    Article  PubMed  Google Scholar 

  39. Viciana P, Rubio R, Ribera E, et al. Longitudinal study on adherence, treatment satisfaction, and effectiveness of once-daily versus twice-daily antiretroviral therapy in a Spanish cohort of HIV-infected patients (CUVA study). Enferm Infecc Microbiol Clin. 2008;26:127–134.

    Article  PubMed  Google Scholar 

  40. Smith SR, Rublein JC, Marcus C, et al. A medication self-management program to improve adherence to HIV therapy regimens. Patient Educ Couns. 2003;50:187–199.

    Article  PubMed  Google Scholar 

  41. Bangsberg DR, Bronstone A, Hofman R. A computer-based assessment detects regimen misunderstandings and nonadherence for patients on HIV antiretroviral therapy. AIDS Care. 2002;14:3–15.

    Article  PubMed  CAS  Google Scholar 

  42. Murri R, Ammassari A, Nappa S, et al. Physician estimates of adherence and the patient-physician relationship as a setting to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31:S158–S162.

    Article  PubMed  Google Scholar 

  43. Kidder DP, Wolitski RJ, Campsmith ML, et al. Health status, health care use, medication use, and medication adherence among homeless and housed people living with ENDS. Am J Public Health. 2007;97:2238–2245.

    Article  PubMed  Google Scholar 

  44. Leaver CA, Bargh G, Dunn JR, et al. The effects of housing status on health-related outcomes in people living with HIV: a systematic review of the literature. AIDS Behav. 2007;11:S85–S100.

    Article  Google Scholar 

  45. Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG, Flanigan TP. Human immunodeficiency virus in correctional facilities: a review. Clin Infect Dis. 2002;35:305–312.

    Article  PubMed  Google Scholar 

  46. Binswanger IA, Stern MF, Deyo RA, et al. Release from prison – A high risk of death for former inmates. N Engl J Med. 2007;356:157–165.

    Article  PubMed  CAS  Google Scholar 

  47. Robison LS, Westfall AO, Mugavero MJ, et al. Short-term discontinuation of HAART regimens more common in vulnerable patient populations. AIDS Res Hum Retroviruses. 2008;24:1347–1355.

    Article  PubMed  CAS  Google Scholar 

  48. Gross R, Zhang Y, Grossberg R. Medication refill logistics and refill adherence in HIV. Pharmacoepidemiol Drug Safety. 2005;14:789–793.

    Article  CAS  Google Scholar 

  49. Mannheimer SB, Mukherjee R, Hirschhorn LR, et al. The CASE adherence index: a novel method for measuring adherence to antiretroviral therapy. AIDS Care. 2006;18:853–861.

    Article  PubMed  CAS  Google Scholar 

  50. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43:S79–S87.

    Article  PubMed  Google Scholar 

  51. Mounzer, K. Choosing an optimal second-line regimen for a patient with intermittent adherence [Clinical care options web site]. 2008. Available at: http://www.clinicaloptions.com/HIV.aspx. Accessed January 9, 2009.

  52. Glass TR, De Geest S, Hirschel B, et al. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antiviral Ther. 2008;13:77–85.

    CAS  Google Scholar 

  53. Kaplan S, Mounzer K. Antiretroviral therapy in HIV-infected patients with multidrug-resistant virus: applying the guidelines to practice. AIDS Patient Care STDs. 2008;22:931–940.

    Article  PubMed  Google Scholar 

  54. Kredo T, Van der Walt J, Siegfried N, et al. Therapeutic drug monitoring of antiretrovirals for people with HIV. Cochrane Database Syst Rev. 2008; (Issue 3). Art. No.: CD007268. DOI:10.1002/14651858.CD007268.

    Google Scholar 

  55. Dolin R, Masur H, Saag M. AIDS therapy. Philadelphia, PA: Churchill Livingstone; 1999.

    Google Scholar 

  56. Barrios A, Rendon AL, Gallego O, et al. Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin Trials. 2004;5:201–205.

    Article  PubMed  Google Scholar 

  57. Petersen K, Riddle MS, Jones LE, et al. Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy. AIDS. 2005;19:1700–1702.

    Article  PubMed  CAS  Google Scholar 

  58. Chesney MA. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr. 2006;43:S149–S155.

    Article  PubMed  Google Scholar 

  59. Simoni JM, Pearson C, Pantalone D, et al. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load: a meta-analytic Review of Randomized Controlled Trials. J Acquir Immune Defic Syndr. 2006;43:S23–S35.

    Article  PubMed  Google Scholar 

  60. Rueda S, Park-Wyllie L, Bayoumi A, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev. 2006; (Issue 3). Art. No.: CD001442.DOI:10.1002/14651858.CD001442.pub2.

    Google Scholar 

  61. Amico KR, Harman J, Johnson B. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996–2004. J Acquir Immune Defic Syndr. 2006;41:285–297.

    Article  PubMed  Google Scholar 

  62. Simoni J, Frick P, Pantalone D, et al. Antiretroviral adherence interventions: a review of current literature and ongoing studies. Topics HIV Med. 2003;11:185–198.

    Google Scholar 

  63. Jones DL, McPherson-Baker S, Lydston D, et al. Efficacy of a group medication adherence intervention among HIV positive women: The SMART/EST women’s project. AIDS Behav. 2007;11:79–86.

    Article  PubMed  Google Scholar 

  64. Jones DL, Ishii M, LaPerriere A, et al. Influencing medication adherence among women with AIDS. AIDS Care. 2003;15:463–474.

    Article  PubMed  CAS  Google Scholar 

  65. Rawlings MK, Thompson M, Farthing C, et al. Impact of an educational program on efficacy and adherence with a twice-daily Lamivudine/Zidovudine/Abacavir regimen in underrepresented HIV-infected patients. J Acquir Immune Defic Syndr. 2003;34:174–183.

    Article  PubMed  Google Scholar 

  66. Wagner G, Kanouse D, Golinelli D, et al. Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: a randomized controlled trial (CCTG 578). AIDS. 2006;20:1295–1302.

    Article  PubMed  Google Scholar 

  67. Golin C, Earp J, Tien H-C, et al. A 2-Arm, randomized, controlled trial of a motivational interviewing-based intervention to improve adherence to antiretroviral therapy (ART) among patients failing or initiating ART. J Acquir Immune Defic Syndr. 2006;42:42–51.

    Article  PubMed  Google Scholar 

  68. DiIorio C, McCarty F, Resnicow K, et al. Using motivational interviewing to promote adherence to antiretroviral medications: a randomized controlled study. Aids Care. 2008;20:273–283.

    Article  PubMed  CAS  Google Scholar 

  69. Tuldra A, Fumaz C, Ferrer MJ, et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;25:221–228.

    Article  PubMed  CAS  Google Scholar 

  70. Pradier C, Bentz L, Spire B, et al. Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. HIV Clin Trials. 2003;4:121–131.

    Article  PubMed  Google Scholar 

  71. Reynolds N, Testa M, Su M, et al. Telephone support to improve antiretroviral medication adherence: a multisite, randomized controlled trial. J Acquir Immune Defic Syndr. 2008;47:62–68.

    Article  PubMed  Google Scholar 

  72. Mannheimer S, Morse E, Matts J, et al. Sustained benefit from a long-term antiretroviral adherence intervention: results of a large randomized clinical trial. J Acquir Immune Defic Syndr. 2006;43:S41–S47.

    Article  PubMed  Google Scholar 

  73. Safren SA, Hendriksen ES, Desousa N, et al. Use of an on-line pager system to increase adherence to antiretroviral medications. AIDS Care. 2003;15:787–793.

    Article  PubMed  CAS  Google Scholar 

  74. Andrade A, McGruder H, Wu A, et al. A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clin Infect Dis. 2005;41:875–882.

    Article  PubMed  Google Scholar 

  75. Wise J, Operario D. Use of electronic reminder devices to improve adherence to antiretroviral therapy: a systematic review. AIDS Patient Care STDs. 2008;22:495–504.

    Article  PubMed  Google Scholar 

  76. Petersen M, Wang Y, van der Laan M, et al. Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin Infect Dis. 2007;45:908–915.

    Article  PubMed  CAS  Google Scholar 

  77. Lucas G, Flexner C, Moore R. Directly administered antiretroviral therapy in the treatment of HIV infection: benefit or burden? AIDS Patient Care STDs. 2002;16:527–535.

    Article  PubMed  Google Scholar 

  78. Kirkland LR, Fischl MA, Tashima KT, et al. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clin Infect Dis. 2002;34:511–518.

    Article  PubMed  CAS  Google Scholar 

  79. Babudieri S, Aceti A, D’Offizi GP, Carbonara S, Starnini G. Directly observed therapy to treat HIV infection in prisoners. JAMA. 2000;284:179–180.

    Article  PubMed  CAS  Google Scholar 

  80. Lucas G, Mullen A, Weidle P, Hader S, McCaul M, Moore R. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis. 2006;42:1628–1635.

    Article  PubMed  CAS  Google Scholar 

  81. Altice FL, Maru D, Bruce RD, Springer S, Friedland G. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis. 2007;45:770–778.

    Article  PubMed  CAS  Google Scholar 

  82. Levy RW, Rayner CR, Fairley CK, et al. Multidisciplinary HIV adherence intervention: a randomized study. Aids Patient Care and Stds 2004;18:728–735.

    Article  PubMed  CAS  Google Scholar 

  83. Safren SA, Boswell S, Johnson W, Salomon L, Mayer K. Initial outcome of an on-line paging system (Medimom) to increase adherence to antiretroviral medications. In: Conference on Retroviruses and Opportunistic Infections. Chicago, IL; 2001:Abstract No. 480.

    Google Scholar 

  84. Des Jarlais DC, Paone D, Milliken J, et al. Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Lancet. 1999;353:1657–1661.

    Article  PubMed  CAS  Google Scholar 

  85. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921–929.

    Article  PubMed  CAS  Google Scholar 

  86. Freedberg KA, Hirschhorn LR, Schackman BR, et al. Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. J Acquir Immune Defic Syndr. 2006;43:S113–S118.

    Article  PubMed  Google Scholar 

  87. Goldie SJ, Paltiel AD, Weinstein MC, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003;115:632–641.

    Article  PubMed  Google Scholar 

  88. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001;344:817–823.

    Article  PubMed  CAS  Google Scholar 

  89. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344:824–831.

    Article  PubMed  CAS  Google Scholar 

  90. ADAP programs fight for survival with less money and more clients. North Carolina’s list tops 700 by midyear. AIDS Alert. 2004;19:85, 7–9.

    Google Scholar 

  91. More patients seek drugs through ADAPs, creating $50 million deficit. AIDS Alert. 2001;16:53–56.

    Google Scholar 

  92. CDC. reported tuberculosis in the United States, 2007. 2008. Available at: http://www.cdc.gov/tb/statistics/reports/2008/default.htm. Accessed on January 9, 2009.

  93. Horsburgh CR, Feldman S, Ridzon R. Practice guidelines for the treatment of tuberculosis. Clin Infect Dis. 2000;31:633–639.

    Article  PubMed  Google Scholar 

  94. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis – consensus statement of the public health tuberculosis guidelines panel. J Am Med Assoc. 1998;279:943–948.

    Article  CAS  Google Scholar 

  95. Hirsch-Moverman Y, Daftary A, Franks J, et al. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tubercular Lung Dis. 2008;12:1235–1254.

    CAS  Google Scholar 

  96. Burman WJ, Cohn DL, Rietmeijer CA, et al. Noncompliance with directly observed therapy for tuberculosis. Epidemiology and effect on the outcome of treatment. Chest. 1997;111:1168–1673.

    Article  PubMed  CAS  Google Scholar 

  97. Blumberg HM, Burman WJ, Chaisson RE, et al. American thoracic society/centers for disease control and prevention/infectious diseases society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603–662.

    Article  PubMed  Google Scholar 

  98. Franke MF, Appleton SC, Bayona J, et al. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis 2008;46:1844–1851.

    Article  PubMed  Google Scholar 

  99. Pozsik C, Kinney J, Breeden D, et al. Approaches to Improving Adherence to Antituberculosis Therapy – South Carolina and New York, 1986–1991. Morb Mortal Wkly Rev. 1993;42:74–75, 81.

    Google Scholar 

  100. Liu Q, Abba K, Alejandria M, et al. Reminder systems and late patient tracers in the diagnosis and management of tuberculosis. Cochrane Database Syst Rev. 2008:Art. No.:CD006594. DOI: 10.1002/14651858.CD006594.pub2.

    Google Scholar 

  101. Jasmer R, Seaman C, Gonzalez L, et al. Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy. Am J Respir Crit Care Med. 2004;170:561–566.

    Article  PubMed  Google Scholar 

  102. Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database of Syst Rev. 2007:Art. No.: CD003343. DOI: 10.1002/14651858.CD003343.pub3.

    Google Scholar 

  103. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug-resistance and relapse in tuberculosis. N Engl J Med. 994;330:1179–1184.

    Google Scholar 

  104. Augenbraun M, Bachmann L, Wallace T, et al. Compliance with doxycycline therapy in sexually transmitted diseases clinics. Sex Transm Dis. 1998;25:1–4.

    Article  PubMed  CAS  Google Scholar 

  105. Katz BP, Zwickl BW, Caine VA, et al. Compliance with antibiotic therapy for Chlamydia trachomatis and Neisseria gonorrhoeae. Sex Transm Dis. 1992;19:351–354.

    Article  PubMed  CAS  Google Scholar 

  106. Reyes H, Guiscafre H, Munoz O, et al. Antibiotic noncompliance and waste in upper respiratory infections and acute diarrhea. J Clin Epidemiol. 1997;50:1297–1304.

    Article  PubMed  CAS  Google Scholar 

  107. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother. 2002;49:897–903.

    Article  PubMed  CAS  Google Scholar 

  108. Bachmann LH, Stephens J, Richey CM, et al. Measured versus self-reported compliance with doxycycline therapy for Chlamydia-associated syndromes: high therapeutic success rates despite poor compliance. Sex Transm Dis. 1999;26:272–278.

    Article  PubMed  CAS  Google Scholar 

  109. Alexiou Z, Mouktaroudi M, Koratzanis G, et al. The significance of compliance for the success of antimicrobial prophylaxis in recurrent lower urinary tract infections: the Greek experience. Int J Antimicrob Agen. 2007;30:40–43.

    Article  CAS  Google Scholar 

  110. Wright J, Htun Y, Leong G, et al. Evaluation of the use of calendar blister packaging on patient compliance with STD Syndromic Treatment Regimens. Sex Transm Dis. 1999;26:556–563.

    Article  PubMed  CAS  Google Scholar 

  111. Beaucage K, Lachance-Demers H, Ngo TT, et al. Telephone follow-up of patients receiving antibiotic prescriptions from community pharmacies. Am J Health Sys Pharm. 2006;63:557–563.

    Article  Google Scholar 

  112. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666–674.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

I would like to acknowledge the helpful input and guidance of Dr. Karam Mounzer in the development of this chapter, as well as Jeremy Goldstein for assistance with images and layout.

Author information

Authors and Affiliations

  1. Department of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Karen Moore Goldstein MD, MSPH (Staff Physician, The Jonathan Lax Treatment Center; Clinical Assistant Professor)

Authors
  1. Karen Moore Goldstein MD, MSPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karen Moore Goldstein MD, MSPH .

Editor information

Editors and Affiliations

  1. Duke University Medical Center, Erwin Road 2424, Durham, 27705, North Carolina, USA

    Hayden Bosworth

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Goldstein, K.M. (2010). Adherence in the Treatment of HIV and Other Infectious Diseases. In: Bosworth, H. (eds) Improving Patient Treatment Adherence. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-5866-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-5866-2_11

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-5865-5

  • Online ISBN: 978-1-4419-5866-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation